Skip to content
About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Long COVID
Cocaine Intoxication
Migraine
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
Monkeypox
Smallpox
COVID-19
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
TNX-1300
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-801
TNX-1800
Broad Spectrum Antivirals
Rare Disease
TNX-2900
Scientific Presentations
Expanded Access Policy
Medicines
Clinical Trials
News & Events
Tonix in the News
Press Releases
Investor Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
August 2015
The AtEase Study: An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD